Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
Japan's Ono Pharmaceutical is paying $280 million upfront to acquire Ionis Pharmaceutical’s phase 2-stage antisense oligonucleotide for a rare type of blood cancer.
Japan's Ono Pharmaceutical is paying $280 million upfront to acquire Ionis Pharmaceutical’s phase 2-stage antisense oligonucleotide for a rare type of blood cancer.
